Mostrar el registro sencillo de la publicación

dc.contributor.authorEcheverría, Cesar
dc.contributor.authorMartin, Aldo
dc.contributor.authorSimon, Felipe
dc.contributor.authorSalas, Cristian O
dc.contributor.authorNazal, Mariajesus
dc.contributor.authorVarela, Diego
dc.contributor.authorPérez-Castro, Ramón
dc.contributor.authorSantibanez, Juan F
dc.contributor.authorValdés-Valdés, Ricardo O
dc.contributor.authorForero-Doria, Oscar
dc.contributor.authorEcheverría, Javier
dc.date.accessioned2022-10-25T19:48:53Z
dc.date.available2022-10-25T19:48:53Z
dc.date.issued2022
dc.identifier.urihttp://repositorio.ucm.cl/handle/ucm/4137
dc.description.abstractBackground: There is abundant ethnopharmacological evidence the uses of regarding Solanum species as antitumor and anticancer agents. Glycoalkaloids are among the molecules with antiproliferative activity reported in these species. Purpose: To evaluate the anticancer effect of the Solanum glycoalkaloid tomatine in hepatocellular carcinoma (HCC) in vitro (HepG2 cells) and in vivo models. Methods: The resazurin reduction assay was performed to detect the effect of tomatine on cell viability in human HepG2 cell lines. Programmed cell death was investigated by means of cellular apoptosis assays using Annexin V. The expression of cancer related proteins was detected by Western blotting (WB). Reactive oxygen species (ROS) and calcium were determined by 2,7-dichlorodihydrofluorescein diacetate and Fluo-4, respectively. Intrahepatic HepG2 xenograft mouse model was used to elucidate the effect of tomatine on tumor growth in vivo. Results and Discussion: Tomatine reduced HepG2 cell viability and induced the early apoptosis phase of cell death, consistently with caspase-3, -7, Bcl-2 family, and P53 proteins activation. Furthermore, tomatine increased intracellular ROS and cytosolic Ca+2 levels. Moreover, the NSG mouse xenograft model showed that treating mice with tomatine inhibited HepG2 tumor growth. Conclusion: Tomatine inhibits in vitro and in vivo HCC tumorigenesis in part via modulation of p53, Ca+2, and ROS signalling. Thus, the results suggest the potential cancer therapeutic use of tomatine in HCC patientses_CL
dc.language.isoenes_CL
dc.rightsAtribución-NoComercial-SinDerivadas 3.0 Chile*
dc.rightsAtribución-NoComercial-SinDerivadas 3.0 Chile*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/cl/*
dc.sourceFrontiers in Pharmacology, 13, 1003264es_CL
dc.subjectSolanum glycoalkaloidses_CL
dc.subjectTomatine,es_CL
dc.subjectAntitumoral activityes_CL
dc.subjectHepatocellular carcinomaes_CL
dc.subjectApoptosises_CL
dc.subjectCaspase pathwayses_CL
dc.titleIn Vivo and in vitro antitumor activity of tomatine in hepatocellular carcinomaes_CL
dc.typeArticlees_CL
dc.ucm.facultadFacultad de Medicinaes_CL
dc.ucm.indexacionScopuses_CL
dc.ucm.indexacionIsies_CL
dc.ucm.uriwww.frontiersin.org/articles/10.3389/fphar.2022.1003264/fulles_CL
dc.ucm.doidoi.org/10.3389/fphar.2022.1003264es_CL


Ficheros en la publicación

FicherosTamañoFormatoVer

No hay ficheros asociados a esta publicación.

Esta publicación aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo de la publicación

Atribución-NoComercial-SinDerivadas 3.0 Chile
Excepto si se señala otra cosa, la licencia de la publicación se describe como Atribución-NoComercial-SinDerivadas 3.0 Chile